File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Determinants of persistent significant fibrosis during long-term nucleoside analogue therapy in chronic hepatitis B: an interim analysis
Title | Determinants of persistent significant fibrosis during long-term nucleoside analogue therapy in chronic hepatitis B: an interim analysis |
---|---|
Authors | |
Issue Date | 2016 |
Citation | The 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. How to Cite? |
Abstract | Background: Changes in liver stiffness measurements (LSM) during long-term nucleoside analogue therapy in chronic hepatitis B (CHB) have not been well-investigated. Methods: We recruited CHB patients on long-term nucleoside analogue herapy with persistent virologic suppression (HBV DNA <20 IU/ml on 3 occasions of at least 6 months apart) and with previous LSM indicating significant liver fibrosis, as defined by EASL-ALEH Guidelines (>9.0 kPa for normal alanine aminotransferase [ALT] and >12.0 kPa for ALT >1-5 x upper limit of normal). Assessment included anthropometric measurements, HBV virology, and reassessment transient elastography and controlled attenuation parameter (CAP) measurements by FibroScan® (Echosens, Paris, France). Hepatic steatosis was defined as CAP ~222 dB/m. Results: In this interim analysis, 119 CHB patients (77.3% male) were recruited. Mean age at reassessment and mean duration of nucleoside analogue therapy was 56.1 (±10.4) years and 8.5 (±3.1) years respectively. 38 patients (31.9%) had persistent liver fibrosis. Patients with persistent liver fibrosis, when compared to patients with fibrosis reversal, had a significantly higher mean body-mass index (26.0 kg/m2 and 23.6 kg/m2 respectively, p=0.040), mean systolic blood pressure (144 mmHg and 136 mmHg respectively, p=0.029) and mean diastolic blood pressure (82 mmHg and 77 mmHg respectively, p=0.046). There was no significant difference in the presence of hepatic steatosis among the two groups (65.8% and 55.6% respectively, p=0.290). Conclusion: Metabolic parameters, including body-mass index and blood pressure, could influence fibrosis reversibility during long-term nucleoside analogue therapy. Recruitment is ongoing and the influence of other metabolic parameters (e.g. metabolic syndrome) will be analyzed. |
Persistent Identifier | http://hdl.handle.net/10722/226492 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Cheung, KS | - |
dc.contributor.author | Liu, SHK | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Leung, WK | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2016-06-17T07:44:29Z | - |
dc.date.available | 2016-06-17T07:44:29Z | - |
dc.date.issued | 2016 | - |
dc.identifier.citation | The 25th Conference of the Asian Pacific Association for the Study of the Liver (APASL 2016), Tokyo, Japan, 20-24 February 2016. | - |
dc.identifier.uri | http://hdl.handle.net/10722/226492 | - |
dc.description.abstract | Background: Changes in liver stiffness measurements (LSM) during long-term nucleoside analogue therapy in chronic hepatitis B (CHB) have not been well-investigated. Methods: We recruited CHB patients on long-term nucleoside analogue herapy with persistent virologic suppression (HBV DNA <20 IU/ml on 3 occasions of at least 6 months apart) and with previous LSM indicating significant liver fibrosis, as defined by EASL-ALEH Guidelines (>9.0 kPa for normal alanine aminotransferase [ALT] and >12.0 kPa for ALT >1-5 x upper limit of normal). Assessment included anthropometric measurements, HBV virology, and reassessment transient elastography and controlled attenuation parameter (CAP) measurements by FibroScan® (Echosens, Paris, France). Hepatic steatosis was defined as CAP ~222 dB/m. Results: In this interim analysis, 119 CHB patients (77.3% male) were recruited. Mean age at reassessment and mean duration of nucleoside analogue therapy was 56.1 (±10.4) years and 8.5 (±3.1) years respectively. 38 patients (31.9%) had persistent liver fibrosis. Patients with persistent liver fibrosis, when compared to patients with fibrosis reversal, had a significantly higher mean body-mass index (26.0 kg/m2 and 23.6 kg/m2 respectively, p=0.040), mean systolic blood pressure (144 mmHg and 136 mmHg respectively, p=0.029) and mean diastolic blood pressure (82 mmHg and 77 mmHg respectively, p=0.046). There was no significant difference in the presence of hepatic steatosis among the two groups (65.8% and 55.6% respectively, p=0.290). Conclusion: Metabolic parameters, including body-mass index and blood pressure, could influence fibrosis reversibility during long-term nucleoside analogue therapy. Recruitment is ongoing and the influence of other metabolic parameters (e.g. metabolic syndrome) will be analyzed. | - |
dc.language | eng | - |
dc.relation.ispartof | Conference of the Asian Pacific Association for the Study of the Liver, APASL 2016 | - |
dc.title | Determinants of persistent significant fibrosis during long-term nucleoside analogue therapy in chronic hepatitis B: an interim analysis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Liu, SHK: drkliu@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Leung, WK: waikleung@hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Leung, WK=rp01479 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.identifier.hkuros | 258722 | - |